Evidence map›Paper›PMID 38165444›Full record

ArticleInternational urogynecology journal2024

The Response of the Urinary Microbiome to Botox.

Kasey M Palm, Megan K Abrams, Sarah B Sears, Susan D Wherley, Anood M Alfahmy, Stacy A Kamumbu, Natalie N Chakraborty, Sangeeta T Mahajan, Sherif A El-Nashar, Joseph W Henderson and 9 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International urogynecology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04479709 (The Urinary Microbiome Before and After Treatment With Intradetrusor Onabotulinum Toxin A Injection for Overactive Bladder), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04479709 completednot on this map

The Urinary Microbiome Before and After Treatment With Intradetrusor Onabotulinum Toxin A Injection for Overactive Bladder

Typeobservational_patient_registrySponsorMetroHealth Medical CenterRan2021 to 2022Enrolled60ConditionsOveractive Bladder
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kasey M PalmDivision of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. Kasey.m.roberts@gmail.com.
Megan K AbramsDivision of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Sarah B SearsDivision of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Susan D WherleyDivision of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Anood M AlfahmyDivision of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Stacy A KamumbuCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Natalie N ChakrabortyDivision of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Sangeeta T MahajanDivision of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Sherif A El-NasharDivision of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Joseph W HendersonDivision of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Adonis K HijazDivision of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Jeffrey M MangelDivision of Female Pelvic Medicine and Reconstructive Surgery, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Robert R PollardDivision of Female Pelvic Medicine and Reconstructive Surgery, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Hilmi Al-ShakhshirCenter for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA.
Martin A RetuertoCenter for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA.
Kelly M StellerCenter for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA.
Mohammed ElshaerClinical Pathology Department, Mansoura Faculty of Medicine, Mansoura, Egypt.
Mahmoud A GhannoumCenter for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA.
David SheynDivision of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisOur objective was to evaluate if botox alters the urinary microbiome of patients with overactive bladder and whether this alteration is predictive of treatment response.

methodsThis multicenter prospective cohort study included 18-89-year-old patients undergoing treatment for overactive bladder with 100 units of botox. Urine samples were collected by straight catheterization on the day of the procedure (S1) and again 4 weeks later (S2). Participants completed the Patient Global Impression of Improvement form at their second visit for dichotomization into responders and nonresponders. The microbiome was sequenced using 16s rRNA sequencing. Wilcoxon signed rank and Wilcoxon rank sum were used to compare the microbiome, whereas chi-square, Wilcoxon rank sum, and the independent t-test were utilized for clinical data.

resultsSixty-eight participants were included in the analysis. The mean relative abundance and prevalence of Beauveria bassiana, Xerocomus chrysenteron, Crinipellis zonata, and Micrococcus luteus were all found to increase between S1 and S2 in responders; whereas in nonresponders the mean relative abundance and prevalence of Pseudomonas fragi were found to decrease. The MRA and prevalence of Weissella cibaria, Acinetobacter johnsonii, and Acinetobacter schindleri were found to be greater in responders than nonresponders at the time of S1. Significant UM differences in the S1 of patients who did (n = 5) and did not go on to develop a post-treatment UTI were noted.

conclusionsLongitudinal urobiome differences may exist between patients who do and do not respond to botox.

Indexed as

Botulinum Toxins, Type AMicrobiotaUrinary Bladder, OveractiveAdolescentAdultAgedAged, 80 and overHumansMiddle AgedProspective StudiesRNA, Ribosomal, 16SYoung AdultBotulinum Toxins, Type ARNA, Ribosomal, 16SBotoxUrinary MicrobiomeUrobiomeUrogynecology

Identifiers

PMID38165444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.